- In April 2024, Otsuka Medical Devices Co., Ltd. announced a definitive agreement to transfer the distribution of the Diamondback 360 Coronary Orbital Atherectomy System (OAS) in Japan to Abbott Medical Japan LLC. This strategic move aims to expand the market reach of the Diamondback 360 system by leveraging Abbott's established distribution network
- In November 2024, Philips announced the enrollment of the first patient in the U.S. THOR IDE clinical trial, evaluating a combined laser atherectomy and intravascular lithotripsy catheter. This innovative device aims to simplify peripheral artery disease (PAD) treatment by integrating two therapies into a single procedure, potentially reducing procedural complexity and improving patient outcomes
- In November 2024, Medtronic announced results from two studies evaluating the utility of atherectomy for peripheral endovascular interventions, presented as late-breaking data presentations at VIVA 2024. These studies added to the body of research demonstrating the safety and effectiveness of atherectomy as a treatment for peripheral arterial disease
- In October 2023, Cardio Flow announced it received US Food and Drug Administration (FDA) 510(k) clearance for the company's FreedomFlow orbital atherectomy peripheral platform, expanding the available treatment options for peripheral arterial disease.
- In February 2023, the FDA issued an early alert about potential risks associated with the Rotarex Atherectomy Systems (Bard Peripheral Vascular), specifically concerning helix fracture or breakage. This highlights the ongoing need for device vigilance and adherence to updated instructions for safe use.
